This webcast features: Andrew Hanneman, Scientific Advisor, Charles River Laboratories

One of the major challenges to developing successful biopharmaceutical products is understanding and characterizing potential impurities. Finding the source and magnitude of these impurities allows us to minimize and remove them during the manufacturing process to create a safe and effective drug. Development also needs to include supporting stability and forced degradation studies to ensure long-term safety and efficacy.

Some impurities, such as protein degradants, host cell proteins, and various small molecules and polymers, require detailed mass spectrometry (MS)-based characterization. This webinar will examine the approaches implemented to characterize impurities by mass spectrometry.

Key topics to be discussed include:

Just fill out the form below to watch the recorded webcast now.